M. Alexander Otto began his reporting career early in 1999 covering the pharmaceutical industry for a national pharmacists' magazine and freelancing for the Washington Post and other newspapers. He then joined BNA, now part of Bloomberg News, covering health law and the protection of people and animals in medical research. Alex next worked for the McClatchy Company. Based on his work, Alex won a year-long Knight Science Journalism Fellowship to MIT in 2008-2009. He joined the company shortly thereafter. Alex has a newspaper journalism degree from Syracuse (N.Y.) University and a master's degree in medical science -- a physician assistant degree -- from George Washington University. Alex is based in Seattle.
News
Intensive surveillance after CRC resection does not improve survival
There was no significant difference in recurrence-free or overall survival.
News
Atezolizumab strikes out in ovarian cancer
Atezolizumab did not extend progression-free survival.
News
High-dose TRT: A new standard of care for LS-SCLC?
Though it conferred a significant improvement in survival without increasing toxicity, high-dose thoracic radiotherapy should not be the new...
News
HPV vaccine shown to substantially reduce cervical cancer risk
A review of more than 1 million girls/women vaccinated in 2006-2017 shows a substantial reduction in the risk for invasive cervical cancer.
News
Neoadjuvant mFOLFIRINOX improves DFS, OS effect uncertain
Modified FOLFIRINOX should be considered as a new option for T3-T4 rectal cancer, according to an investigator.
News
Predicting complications of cytoreductive nephrectomy in metastatic RCC
Registry data revealed factors associated with intraoperative and postoperative complications.
News
Lorlatinib: Another first-line option for ALK-positive NSCLC?
Lorlatinib bested crizotinib as first-line therapy for ALK-positive non–small cell lung cancer.
News
Metformin may delay prostate cancer progression, randomized trial suggests
The data are “hypothesis generating” but not definitive, according to a study discussant.
News
AI algorithm on par with radiologists as mammogram reader
Combining the algorithm with first-reader radiologists revealed more breast cancer cases than combining first- and second-reader radiologists.
News
If PPIs are onboard, atezolizumab may not work for bladder cancer
Proton pump inhibitor use was associated with worse overall and progression-free survival among patients on atezolizumab.
News
FOLFOXIRI tops doublets as bevacizumab backbone for mCRC
A pooled analysis showed better overall survival with upfront FOLFOXIRI plus bevacizumab.
News
Atezolizumab TNBC indication ‘in jeopardy’ because of phase 3 results
Negative results from the IMpassion131 trial may jeopardize the U.S. approval of atezolizumab in breast cancer.
News
AI improves diagnostic accuracy in cervical cancer
A computer model outperformed traditional radiology in identifying lymph node involvement in cervical cancer.
News
PEGPH20 strikeout raises doubts about stroma-targeting agents in pancreatic cancer
There was no improvement in progression-free or overall survival when pegvorhyaluronidase alfa was added to nab-paclitaxel and gemcitabine.